Blog of Signaling Pathways

Myricetin: A Potent Anti-Amyloidogenic Polyphenol against Superoxide Dismutase 1 Aggregation

39 views | Oct 04 2023

Myricetin, a plant flavonoid, has demonstrated potent inhibitory effects on SOD1 aggregation in ALS through a combination of molecular dynamics simulations and experimental observations, suggesting its potential as a therapeutic inhibitor for the disease. [Read the Full Post]

The ensured proliferative capacity of myoblast in serum-reduced conditions with Methyl-β-cyclodextrin

17 views | Oct 04 2023

This study demonstrates that Methyl-β-cyclodextrin (MβCD) can effectively inhibit the differentiation of myoblasts into myotubes and maintain their proliferative capacity in a serum-reduced medium, providing valuable insights for the large-scale production of muscle fibers for cultured meat. [Read the Full Post]

NR4A1 Aggravates Myocardial Ischaemia-Reperfusion Injury by Inhibiting OPA1-Mediated Mitochondrial Fusion

14 views | Oct 04 2023

NR4A1 inhibits OPA1 expression, disrupts mitochondrial dynamics, and activates the STING and NF-κB pathways, exacerbating myocardial ischemia-reperfusion injury (IR) and leading to mitochondrial damage, increased apoptosis, and inflammatory reactions in cardiomyocytes. [Read the Full Post]

Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602)

18 views | Oct 04 2023

The clinical trial comparing an olanzapine-based antiemetic regimen with and without an NK-1 receptor antagonist did not demonstrate sufficient evidence to support the removal of the NK-1 receptor antagonist for preventing chemotherapy-induced nausea and vomiting. [Read the Full Post]

Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments

0 views | Oct 04 2023

The review discusses the development of selective CDK9 inhibitors and PROTAC degraders for cancer treatment, emphasizing the need for further research to understand their mechanisms and identify suitable tumor genotypes and combination treatments. [Read the Full Post]

Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease

36 views | Oct 03 2023

The novel RIPK2 inhibitor Zharp2-1 shows promising potential for the treatment of inflammatory bowel disease (IBD) based on its ability to effectively block RIPK2 kinase function, inhibit NOD-mediated signaling, and ameliorate colitis symptoms in preclinical studies. [Read the Full Post]

HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy

41 views | Oct 03 2023

The evolving understanding of HDL's complex functions beyond its cholesterol content, including its role in reverse cholesterol transport, suppression of inflammatory signaling, and protection against oxidative modifications, has led to the realization that HDL-C levels alone do not necessarily reflect HDL function in atherosclerotic cardiovascular disease (ASCVD). [Read the Full Post]

Up-regulation of MELK by E2F1 promotes the proliferation in cervical cancer cells

32 views | Oct 03 2023

The study demonstrated that MELK plays a vital role in cervical cancer cell proliferation, and targeting MELK could be a potential therapeutic approach for the treatment of cervical cancer. [Read the Full Post]

5-Fluorouracil-Loaded PLGA Nanoparticles: Formulation, Physicochemical Characterisation, and In Vitro Anti-Cancer Activity

16 views | Oct 03 2023

The study aimed to develop polymeric nanoparticles loaded with 5-fluorouracil (FU) using the interfacial deposition method, resulting in spherical and homogenous nanoparticles with a nanometric size of 200 nm suitable for intravenous delivery, and showed improved cytotoxic effect compared to the marketed formulation Fluracil. [Read the Full Post]

The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo

31 views | Oct 03 2023

The study demonstrated that the small-molecule compound SR18662, which inhibits Krüppel-like factor 5 (KLF5), significantly reduced the growth and proliferation of colorectal cancer cells, induced cell cycle arrest and apoptosis, modulated key signaling pathways, and inhibited xenograft growth in mice, indicating its potential as a therapeutic candidate for colorectal cancer. [Read the Full Post]

Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase

51 views | Oct 02 2023

This study demonstrates that increased infiltration of neutrophils and the release of neutrophil elastase play a significant role in Doxorubicin-induced cardiotoxicity, highlighting potential therapeutic interventions for this condition. [Read the Full Post]

Lassa Virus Cell Entry via Dystroglycan Involves an Unusual Pathway of Macropinocytosis

0 views | Oct 02 2023

This study revealed that Lassa virus enters human cells via a unique macropinocytosis-related pathway involving dystroglycan, and identified cellular kinases, including human hepatocyte growth factor receptor (HGFR), as potential targets for antiviral therapy. [Read the Full Post]

ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to FGFR1 inhibitors through amino acid metabolic reprogramming

0 views | Oct 02 2023

This study reveals that targeting FGFR1 and mTOR in combination can overcome drug resistance in T-cell acute lymphoblastic leukemia (T-ALL) by inhibiting ATF4-mediated amino acid metabolic reprogramming. [Read the Full Post]

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

0 views | Oct 02 2023

This review discusses the concept of relapsed chronic lymphocytic leukemia (CLL), available treatment options, and emerging therapies, emphasizing the need for individualized therapy selection and the ongoing research in this field. [Read the Full Post]

APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice

0 views | Oct 02 2023

APX-115, a pan-NOX inhibitor, shows potential as a promising therapeutic agent for the treatment of diabetic nephropathy by improving pancreatic beta cell function, reducing lipid levels, restoring kidney damage markers, and exerting anti-inflammatory effects. [Read the Full Post]

[Therapeutic drug monitoring of antipsychotic drugs in routine psychiatric practice]

65 views | Oct 01 2023

This study examined the relationship between daily doses of antipsychotic drugs, their serum concentrations, and patient characteristics in the treatment of schizophrenia, highlighting the importance of therapeutic drug monitoring and individual patient factors on drug exposure. [Read the Full Post]

C5aR1 is a master regulator in Colorectal Tumorigenesis via Immune modulation

22 views | Oct 01 2023

Activation of the complement system, specifically C5a/C5aR1 signaling, plays a crucial role in colorectal tumorigenesis by recruiting myeloid-derived suppressor cells, impairing CD8+ T cell function, and modulating cytokine and chemokine production. [Read the Full Post]

Safety and tolerability of oral vorolanib for neovascular (wet) age-related macular degeneration: a phase I, open-label study

31 views | Oct 01 2023

The study demonstrated that oral vorolanib improved visual outcomes in participants with neovascular age-related macular degeneration (nAMD) while maintaining a manageable safety profile. [Read the Full Post]

Effectiveness of netarsudil 0.02% in lowering intraocular pressure in patients with secondary glaucoma

64 views | Oct 01 2023

Netarsudil, 0.02%, was found to be effective in lowering intraocular pressure (IOP) in patients with secondary forms of glaucoma, especially uveitic glaucoma. [Read the Full Post]

Thalidomide derivatives as nanomolar human neutrophil elastase inhibitors: Rational design, synthesis, antiproliferative activity and mechanism of action

0 views | Oct 01 2023

In this study, rationally designed human neutrophil elastase inhibitors derived from thalidomide demonstrated strong inhibitory activity, competitive mode of action, and promising antiproliferative effects against cancer cells, with compound 4f showing comparable HNE inhibition to sivelestat and inducing cell cycle arrest and apoptosis in T47D breast carcinoma cells. [Read the Full Post]